Prelim Study Of Association Between Nutritional Indices, Psychosocial Factors, Cytokines & Survival Advanced Cancer Pati
Funder
National Health and Medical Research Council
Funding Amount
$24,820.00
Summary
This preliminary project aims to evaluate associations between cancer cachexia, psychosocial factors and cytokine levels in blood. The final decline of most patients with advanced cancer is associated with the cancer cachexia syndrome, triggered in part by cytokine release. Measuring cytokines may enable identification of patients about to enter this final stage. Further, factors like mood and social support appear to alter cytokine levels. The associations established by this study may point to ....This preliminary project aims to evaluate associations between cancer cachexia, psychosocial factors and cytokine levels in blood. The final decline of most patients with advanced cancer is associated with the cancer cachexia syndrome, triggered in part by cytokine release. Measuring cytokines may enable identification of patients about to enter this final stage. Further, factors like mood and social support appear to alter cytokine levels. The associations established by this study may point to treatment options that can delay the terminal phase while improving quality of life.Read moreRead less
Molecular Classification Of Carcinoma Of Unknown Primary
Funder
National Health and Medical Research Council
Funding Amount
$418,250.00
Summary
Carcinoma of unknown primary (CUP) is the fourth largest cause of cancer death. The condition has a particularly poor outlook, with a median survival of less than one year. Current methods for diagnosis of CUP include histopathology and sophisticated imaging. These are successful in approximately 40% of cases. Frequently the reason for the poor outcome in this disease is that the 60% of patients with CUP for whom no diagnosis is made do not benefit from chemotherapy specifically designed for a p ....Carcinoma of unknown primary (CUP) is the fourth largest cause of cancer death. The condition has a particularly poor outlook, with a median survival of less than one year. Current methods for diagnosis of CUP include histopathology and sophisticated imaging. These are successful in approximately 40% of cases. Frequently the reason for the poor outcome in this disease is that the 60% of patients with CUP for whom no diagnosis is made do not benefit from chemotherapy specifically designed for a particular tumour origin. These patients receive a less effective, generic, chemotherapy. The aim of this project is to use microarrays to identify the gene expression profile in many known tumours to create a molecular fingerprint of the various tumour types. By comparing the fingerprint from a CUP with the database we should be able to identify the true tumour type in CUP, and allow patients to benefit from more specific chemotherapy.Read moreRead less